DexCom (NASDAQ:DXCM) Stock Price Up 5.3% Following Better-Than-Expected Earnings

DexCom, Inc. (NASDAQ:DXCM – Get Free Report)’s share price traded up 5.3% during trading on Friday following a better than expected earnings announcement. The company traded as high as $85.25 and last traded at $84.1520. Approximately 1,425,039 shares changed hands during trading, a decline of 71% from the average session volume of 4,995,772 shares. The stock had previously closed at $79.93.

The medical device company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 36.96%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.61 earnings per share.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

  • Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
  • Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
  • Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
  • Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
  • Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
  • Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
  • Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DXCM. Royal Bank Of Canada reiterated an “outperform” rating and set a $105.00 price target (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. UBS Group set a $96.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Tuesday, July 28th. TD Cowen restated a “buy” rating and set a $95.00 price objective on shares of DexCom in a research report on Friday, September 18th. Mizuho set a $100.00 price objective on DexCom in a research report on Tuesday, October 13th. Finally, Benchmark lifted their target price on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, DexCom has an average rating of “Buy” and a consensus target price of $92.91.

View Our Latest Analysis on DXCM

Insiders Place Their Bets

In related news, EVP Jereme M. Sylvain sold 3,638 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $549,537.56. Following the transaction, the director directly owned 29,293 shares in the company, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,822 shares of company stock worth $2,090,833 in the last quarter. Corporate insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Chicago Partners Investment Group LLC increased its position in DexCom by 3.9% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 10,817 shares of the medical device company’s stock valued at $843,000 after acquiring an additional 409 shares in the last quarter. Covestor Ltd raised its stake in shares of DexCom by 79.6% in the third quarter. Covestor Ltd now owns 1,282 shares of the medical device company’s stock worth $111,000 after acquiring an additional 568 shares during the last quarter. Caldwell Trust Co lifted its position in shares of DexCom by 1.8% during the third quarter. Caldwell Trust Co now owns 13,732 shares of the medical device company’s stock worth $1,185,000 after purchasing an additional 241 shares in the last quarter. Rakuten Investment Management Inc. grew its stake in shares of DexCom by 8.7% during the third quarter. Rakuten Investment Management Inc. now owns 101,020 shares of the medical device company’s stock valued at $8,752,000 after purchasing an additional 8,108 shares during the last quarter. Finally, Factory Mutual Insurance Co. grew its stake in shares of DexCom by 4.8% during the third quarter. Factory Mutual Insurance Co. now owns 563,383 shares of the medical device company’s stock valued at $48,614,000 after purchasing an additional 25,553 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a market capitalization of $31.05 billion, a P/E ratio of 32.27, a PEG ratio of 1.38 and a beta of 1.48. The company’s 50 day moving average price is $85.82 and its 200 day moving average price is $74.65.

About DexCom

(Get Free Report)

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.

Further Reading

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.